skip to Main Content

Dr. Philip on the Impact of the PRODIGE 24/CCTG PA.6 Study in Pancreatic Cancer

Dr. Philip on the Impact of the PRODIGE 24/CCTG PA.6 Study in Pancreatic Cancer
Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the impact of the PRODIGE 24/CCTG PA.6 study in pancreatic cancer.

In this phase III study, the use of modified FOLFIRINOX resulted in a significantly better overall survival and disease-free survival (DFS) compared with gemcitabine alone. DFS served as the primary endpoint of the study. These data were the first to demonstrate such a profound benefit with the use of adjuvant chemotherapy, Philip says. Notably, there was no use of radiation therapy in the study. Watch here . . . 


Back To Top